Prostate Cancer Diagnostics
Advertisement
Standard risk assessment plus genomic classification for prostate cancer surveillance helps predict disease progression.
Clarity's head-to-head trial evaluates diagnostic performance of 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11.
18F rhPSMA-7.3 (rhPSMA) PET/MRI imaging is a potential "one-stop shop" for detecting biochemically recurrent prostate cancer.
The CLARIFY trial leveraged PSMA PET imaging for personalized prostate cancer treatment and detecting distant metastases.
Advanced PSMA PET imaging improved surgical outcomes for patients with high-risk prostate cancer in the CLARIFY trial.
The COBRA study on SAR-bisPSMA for prostate cancer detection will be presented at the EANM 2024 Congress.
Dr. Pobel offers an overview of the ancillary study of the PEACE-1 trial, including how immunohistochemistry was used.
Prognostic and predictive phenotypic biomarkers have been identified for rPFS and OS in de novo mCSPC.
A previous study found 64Cu-SAR-bisPSMA to be safe and effective in identifying prostate cancer lesions in patients with BCR.
Dr. Helfand explores the potential of Clarity's 64Cu-SAR-bisPSMA agent for prostate cancer imaging.
Black patients are often under-represented in oncology clinical trials.
Stockholm3 is a blood-based test for the detection of prostate cancer that has demonstrated beneficial detection rates.
Dr. Kinnaird elaborates on some of the limitations of MRI and benefits of PET/CT staging for locoregional prostate cancer.
PSMA PET/CT can act as a better alternative to MRI, but research on second-generation PSMA PET radioligands is limited.
The FDA has accepted an NDA for TLX007-CDx, a cold kit for the preparation of PSMA-PET imaging for prostate cancer.
About 1 in 12 patients who undergo non-targeted prostate biopsy with a result of GGG 1 PC may have more aggressive cancer.
Patients were sorted into groups based on modifiable lifestyle behaviors and genetic risk.
Researchers trained and externally validated an AI system to detect Gleason grade group 2 or higher cancers.
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.